Posts

Posted on

Y-mAbs Signs License Agreement with SciClone for DANYELZA® (naxitamab-gqgk) and Omburtamab in China

NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced today that it has entered into a license agreement with SciClone Pharmaceuticals International Ltd (“SciClone”) to be the exclusive co-development and commercialization partner of the Company’s antibodies, DANYELZA® (naxitamab-gqgk) for the treatment of patients with relapsed/refractory high-risk neuroblastoma and omburtamab, if approved, for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma in China. DANYELZA (naxitamab-gqgk) 40mg/10mL was approved by the U.S. Food and Drug Administration (“FDA”) on November 25, 2020 and is indicated, in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. The Company plans to resubmit its Biologics License Application (“BLA”) to the FDA for omburtamab by the end of 2020 or in early 2021.

The license agreement includes Greater China, including Mainland China, Taiwan, Hong Kong and Macau. Under the terms of the agreement, SciClone will employ its development, sales, marketing and regulatory expertise to commercialize DANYELZA and omburtamab, if approved, in the territory. All other unpartnered geographies worldwide remain with the Company. Under the terms of the agreement, SciClone will pay Y-mAbs a $20 million upfront payment with the potential for Y-mAbs to receive up to $100 million in additional development, regulatory and sales milestone payments for both programs, as well as double-digit royalties on net sales for DANYELZA and omburtamab in the territory.

“We are very pleased to enter this license agreement with SciClone, and hope to see a DANYELZA and omburtamab, if approved, being made available to appropriate children with unmet medical needs in China. This partnership marks an important milestone in our aim to make our lead product and product candidate globally available,” said Thomas Gad, founder, Chairman and President at Y-mAbs.

“DANYELZA and omburtamab were initially identified and sourced from Memorial Sloan Kettering Cancer Center in New York, and have been developed by Y-mAbs as novel therapies. We believe these antibodies show great promise,” said Hong Zhao, President and Chief Executive Officer of SciClone. “We are excited to partner with Y-mAbs team to commercialize DANYELZA for the treatment of relapsed/refractory high-risk neuroblastoma and omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma, if approved. This strategic partnership recognizes SciClone’s capability as a leading biotech company with integrated platform of development and commercialization.”

Researchers at MSK developed DANYELZA and omburtamab, which are exclusively licensed by MSK to Y-mAbs. As a result of this licensing arrangement, MSK has institutional financial interests in the compounds and in Y-mAbs.

About DANYELZA® (naxitamab-gqgk)

DANYELZA (naxitamab-gqgk) is indicated, in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. This indication was approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory trial. DANYELZA includes a Boxed Warning for serious infusion-related reactions, such as cardiac arrest and anaphylaxis, and neurotoxicity, such as severe neuropathic pain and transverse myelitis. See full Prescribing Information for complete Boxed Warning and other important safety information.

About Y-mAbs

Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including one FDA approved product, DANYELZA® (naxitamab-gqgk), which targets tumors that express GD2, and one pivotal-stage product candidate, omburtamab, which targets tumors that express B7-H3.

About SciClone Pharmaceuticals (Holdings) Limited

SciClone Pharmaceuticals (Holdings) Limited is a leading biopharmaceutical company with an integrated platform for product development and commercialization, focusing on some of the largest and fast-growing therapeutics areas with significant unmet medical needs in China, primarily including oncology and severe infection. Leveraging their integrated platform, SciClone has a proven track record in developing and commercializing a balanced portfolio of high-quality marketed products and innovative pipeline drugs in their focused therapeutic areas. For more information regarding to SciClone, go to: http://www.sciclone.com/ 

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about our business model and development, commercialization and distribution plans; current and future clinical and pre-clinical studies and our research and development programs; expectations related to the timing of the initiation and completion of regulatory submissions; regulatory, marketing and reimbursement approvals; rate and degree of market acceptance and clinical utility as well as pricing and reimbursement levels; retaining and hiring key employees; our commercialization, marketing and manufacturing capabilities and strategy; our intellectual property position and strategy; additional product candidates and technologies; collaborations or strategic partnerships and the potential benefits thereof; expectations related to the use of our cash and cash equivalents, and the need for, timing and amount of any future financing transaction; our financial performance, including our estimates regarding revenues, expenses, capital expenditure requirements; developments relating to our competitors and our industry; and other statements that are not historical facts. Words such as ‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will”, ‘‘would’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with our financial condition and need for additional capital; risks associated with our development work; cost and success of our product development activities and clinical trials; the risks of delay in the timing of our regulatory submissions or failure to receive approval of our drug candidates; the risks related to commercializing any approved pharmaceutical product including the rate and degree of market acceptance of our product candidates; development of our sales and marketing capabilities and risks associated with failure to obtain sufficient reimbursement for our products; the risks related to our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; the risks related to government regulation; risks related to market approval, risks associated with protection of our intellectual property rights; risks related to employee matters and managing growth; risks related to our common stock, risks associated with the pandemic caused by the novel coronavirus known as COVID-19 and other risks and uncertainties affecting the Company including those described in the “Risk Factors” section included in our Annual Report on Form 10-K and in our other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

“DANYELZA” and “Y-mAbs” are registered trademarks of Y-mAbs Therapeutics, Inc.

Contact:

Y-mAbs Therapeutics, Inc.  For SciClone Pharmaceuticals
230 Park Avenue, Suite 3350 CEO Office
New York, NY 10169  
USA  
+1 646 885 8505 +852 29592922
E-mail: [email protected]  Email: [email protected] 



Posted on

Community Bank System Announces Fourth Quarter 2020 Earnings Conference Call

PR Newswire

SYRACUSE, N.Y., Dec. 18, 2020 /PRNewswire/ — Community Bank System, Inc. (NYSE: CBU) invites you to participate in a conference call to discuss the Company’s financial and operating performance during its fourth quarter ended December 31, 2020.


Event: 


Earnings Conference Call – Fourth Quarter 2020 


When: 


Monday, January 25, 2021 at 11:00 a.m. Eastern Time 


How:


By conference call or from a simultaneous web cast 


Access:


Conference Call Dial-In: 


877-317-6789


+1-412-317-6789 – Outside the U.S. & Canada


Webcast:



https://www.webcaster4.com/Webcast/Page/995/39287

 

Mark E. Tryniski, President and Chief Executive Officer, and Joseph E. Sutaris, Executive Vice President and Chief Financial Officer, will provide an overview of fourth quarter 2020 results. They will be joined by Joseph F. Serbun, Executive Vice President and Chief Banking Officer, for the question and answer session.  The management presentation typically lasts approximately 15 minutes, followed by investor questions and discussion. 

The company’s results for the quarter will be released before the market opens on January 25, 2021, and will also be available in the “Investor Relations” section of the company’s website, www.cbna.com.  

The call will also be archived on the company’s website for one year, and can be accessed at any time and at no cost during this period.

About Community Bank System, Inc.

Community Bank System, Inc. operates more than 230 customer facilities across Upstate New York, Northeastern Pennsylvania, Vermont, and Western Massachusetts through its banking subsidiary, Community Bank, N.A. With assets of over $13.8 billion, the DeWitt, N.Y. headquartered company is among the country’s 125 largest banking institutions. In addition to a full range of retail, business, and municipal banking services, the Company offers comprehensive financial planning, insurance and wealth management services through its Community Bank Wealth Management Group and OneGroup NY, Inc. operating units. The Company’s Benefit Plans Administrative Services, Inc. subsidiary is a leading provider of employee benefits administration, trust services, collective investment fund administration and actuarial consulting services to customers on a national scale. Community Bank System, Inc. is listed on the New York Stock Exchange and the Company’s stock trades under the symbol CBU. For more information about Community Bank visit www.cbna.com or https://ir.communitybanksystem.com.

For further information contact:
Joseph Sutaris,
E.V.P. and Chief Financial Officer
(315) 445-7396

Cision View original content:http://www.prnewswire.com/news-releases/community-bank-system-announces-fourth-quarter-2020-earnings-conference-call-301196027.html

SOURCE Community Bank System, Inc.

Posted on

U.S. Patent Office Upholds Validity of Natera’s Early Priority Date ‘592 cfDNA Patent

PR Newswire

SAN CARLOS, Calif., Dec. 18, 2020 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, is pleased that the United States Patent Office granted Natera a significant win when it denied a patentability challenge from a multi-national sequencing company against Natera’s U.S. Patent No. 8,682,592 (‘592 Patent) upholding all claims. Natera’s ‘592 Patent claims early and significant innovations directed to generating genetic data from limited quantities of DNA, including cfDNA. Natera has shown the techniques to be useful in a variety of contexts such as non-invasive prenatal testing, ctDNA molecular residual disease testing in oncology, and donor-derived cfDNA assessment in organ transplant recipients. 

In upholding the patentability of every one of the ‘592 Patent’s claims against this Inter Partes Review (“IPR”) petition, the Patent Office noted that the challenger had “not demonstrated by a preponderance of the evidence that [the claims] are unpatentable.” According to Elizabeth Laughton of Smith Baluch LLP, IPR counsel for Natera, “The Board concluded that all challenged claims were patentable—a result that occurs in only 1 in 5 IPRs that reach a final written decision.”

“The ‘592 Patent describes, amongst other things, core DNA quantitation methods and more sophisticated methods using genotyping, for analyzing tiny amounts of DNA for a variety of applications. We believe that the early priority date of 2005, along with the ideal IPR result, confirms the importance of this patent and Natera’s pioneering leadership in non-invasive genetic testing,” said Matthew Rabinowitz, Executive Chairman of Natera and an inventor of the patent.

About Natera

Natera is a pioneer and global leader in cell-free DNA testing. The mission of the company is to change the management of disease worldwide with a focus on women’s health, oncology, and organ health. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. For more information, visit natera.com. Follow Natera on LinkedIn.

Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to developments in matters under dispute or litigation, the scope of protection we establish and maintain for, and developments or disputes concerning, our intellectual property or other proprietary rights, our efforts to develop and commercialize new product offerings, our ability to successfully increase demand for and grow revenues for our product offerings, whether the results of clinical or other studies will support the use of our product offerings, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in “Risk Factors” in Natera’s recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

Contacts
Investor Relations: Mike Brophy, CFO, Natera, Inc., 650-249-9090
Media: Paul Greenland, VP of Corporate Marketing, Natera, Inc., [email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/us-patent-office-upholds-validity-of-nateras-early-priority-date-592-cfdna-patent-301195801.html

SOURCE Natera, Inc.

Posted on

BioTelemetry Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of BioTelemetry, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – BEAT

BioTelemetry Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of BioTelemetry, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – BEAT

NEW YORK–(BUSINESS WIRE)–
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of BioTelemetry, Inc. (NASDAQ: BEAT) to Royal Philips for $72.00 per share in cash is fair to BioTelemetry shareholders.

Halper Sadeh encourages BioTelemetry shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].

The investigation concerns whether BioTelemetry and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to: (1) obtain the best possible price for BioTelemetry shareholders; (2) determine whether Royal Philips is underpaying for BioTelemetry; and (3) disclose all material information necessary for BioTelemetry shareholders to adequately assess and value the merger consideration. On behalf of BioTelemetry shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh encourages BioTelemetry shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Halper Sadeh LLP

Daniel Sadeh, Esq.

Zachary Halper, Esq.

(212) 763-0060

[email protected]

[email protected]

https://www.halpersadeh.com

KEYWORDS: Illinois New York United States North America

INDUSTRY KEYWORDS: Other Professional Services Professional Services Legal

MEDIA:

Logo
Logo
Posted on

Amazon Announces First Fulfillment Center in South Dakota

Amazon Announces First Fulfillment Center in South Dakota

New 640,000 square-foot site will be in Sioux Falls and create 1,000 full-time jobs

SEATTLE–(BUSINESS WIRE)–
(NASDAQ: AMZN) – Amazon.com, Inc. plans to open its first fulfillment center in the state of South Dakota in Sioux Falls. The site, which is anticipated to launch in 2022, will create 1,000 full-time jobs with industry leading pay and comprehensive benefits starting on day one.

At the new 640,000 square-foot fulfillment center, employees will work alongside Amazon robotics to pick, pack and ship small items to customers such as books, electronics and toys.

Amazon is a great place to work with highly competitive pay, benefits from day one, and training programs for in-demand jobs. On top of Amazon’s industry-leading minimum starting wage of $15 per hour, full-time employees receive comprehensive benefits, including full medical, vision and dental insurance as well as a 401(k) with 50 percent company match, starting on day one. The company also offers up to 20 weeks of maternal and parental paid leave and innovative benefits such as Leave Share and Ramp Back, which give new parents flexibility to support their growing families.

Amazon also offers employees access to innovative programs like Career Choice, where it will pay up to 95 percent of tuition for courses related to in-demand fields, regardless of whether the skills are relevant to a career at Amazon. Since the program’s launch, more than 25,000 employees across the globe have pursued degrees in game design and visual communications, nursing, IT programming and radiology, to name a few.

Key Quotes:

Alicia Boler Davis, Amazon’s Vice President of Global Customer Fulfillment

“We are thrilled to be opening our first fulfillment center in the great state of South Dakota and bringing 1,000 full-time jobs with industry-leading pay and benefits to Sioux Falls. Amazon leverages its scale for good and makes investments to support communities. We appreciate the strong support from local and state leaders throughout the process, and we look forward to supporting the South Dakota community with great delivery options.”

U.S. Senator John Thune

“Today’s announcement serves as a testament to the success of South Dakota’s business-friendly environment. This distribution facility will bring numerous, high-paying jobs and millions of dollars in investment to the city of Sioux Falls and the rest of the region. I am proud of the state’s economic progress and infrastructure investments that have allowed businesses to thrive.”

Governor of South Dakota Kristi Noem

“South Dakota is open for business, and this commitment has put our state in the position to welcome Amazon to Foundation Park. Amazon is investing in South Dakota with 1,000 jobs, including excellent benefits, which will help fuel our state’s growth for the next generation. So on behalf of the entire state, I want to welcome Amazon to South Dakota.”

Sioux Falls Mayor Paul TenHaken

“We are proud to have been selected by Amazon as their next fulfillment center location. Amazon’s decision to invest in our community reflects the company’s confidence in Sioux Falls’ economic climate and excellent workforce. The team at Amazon has been incredible to work with, and we are excited to welcome them to Sioux Falls and tohelp make this partnership a win-win for many years to come.”

Todd Ernst, Board Chair for the Sioux Falls Development Foundation

“It is both an honor and a privilege to welcome Amazon to the Sioux Falls business community. Our commitment to business growth in the region is apparent, and Amazon will be a vital player in our continued efforts to build the economy of Sioux Falls and leverage the attractive power of Foundation Park.”

Amazon in South Dakota:

  • From 2010-2019, Amazon has invested more than $1 million in South Dakota, including infrastructure and compensation to employees in the state.
  • Amazon’s investments in the state contributed an additional more than $469,000 into the state’s GDP over that same time period.
  • Amazon’s worldwide fulfillment network supports businesses of all sizes through its Fulfillment by Amazon offering, and many of those local businesses are based in South Dakota. There are more than 3,000 small and medium business sellers and independent authors in the state growing their businesses with Amazon.

Additional Resources:

About Amazon

Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Fire tablets, Fire TV, Amazon Echo, and Alexa are some of the products and services pioneered by Amazon. For more information, visit amazon.com/about and follow @AmazonNews.

Amazon.com, Inc.

Media Hotline

[email protected]

www.amazon.com/pr

KEYWORDS: Washington South Dakota United States North America

INDUSTRY KEYWORDS: Retail Online Retail

MEDIA:

Logo
Logo
Posted on

Arcadia Biosciences (RKDA) Announces $8.0 Million Registered Direct Offering Priced At-the-Market

— Net proceeds to fuel GoodWheat™ direct-to-consumer, e-commerce and retail sales channel development —

PR Newswire

DAVIS, Calif., Dec. 18, 2020 /PRNewswire/ — Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a leader in science-based approaches to enhancing the quality and nutritional value of crops and food ingredients, today announced that it has entered into definitive agreements with several institutional and other accredited investors for the purchase of 2,618,658 shares of its common stock, at a purchase price per share of $3.055, in a registered direct offering priced at-the-market under Nasdaq rules. Additionally, Arcadia has also agreed to issue to the investors unregistered warrants to purchase up to 2,618,658 shares of common stock. The closing of the offering is expected to occur on or about December 22, 2020, subject to the satisfaction of customary closing conditions. 

The warrants to purchase up to 2,618,658 shares of common stock have an exercise price of $3.00 per share, will be immediately exercisable, and will expire five and one-half years from the issue date.

The gross proceeds to Arcadia, before deducting placement agent fees and other offering expenses, are expected to be approximately $8.0 million. The potential gross proceeds from the exercise of the warrants, if fully exercised on a cash basis, will be approximately $7.86 million. No assurance can be given that any of the warrants will be exercised. Arcadia intends to use the net proceeds from the offering to fund GoodWheat customer acquisition costs Including digital marketing programs, brand and retail channel development and general corporate costs.

H.C. Wainwright & Co. is acting as exclusive placement agent for the offering.

The shares of common stock described above (but not the warrants or the shares of common stock issuable upon exercise of the warrants) are being offered pursuant to a “shelf” registration statement (File 333-224893) filed with the Securities and Exchange Commission (SEC) and declared effective on June 8, 2018. Such shares of common stock may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A prospectus supplement and the accompanying prospectus relating to the offering will be filed with the SEC. Electronic copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, on the SEC’s website at www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by e-mail at [email protected] or by telephone: (646) 975-6996.

The warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Arcadia Biosciences
Arcadia Biosciences (Nasdaq: RKDA) is a leader in science-based approaches to enhancing the quality and nutritional value of crops and food ingredients. The company’s GoodWheat™ branded ingredients deliver health benefits to consumers and enable consumer packaged goods companies to differentiate their brands in the marketplace. Arcadia’s GoodHempTM seed catalog delivers genetically superior hemp seeds, transplants and extracts, applying the company’s proprietary crop innovation technology, ArcaTech™, to an emerging crop. For more information, visit www.arcadiabio.com.

Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company’s expectations regarding the completion of the registered direct offering, potential gross proceeds from the exercise of warrants, satisfaction of closing conditions and use of proceeds therefrom. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, without limitation, market and other conditions, the future capital requirements of the company are different than expected, the trading price of the company’s common stock does not increase to a price that would incentivize the investors to exercise the warrants, the closing conditions related to the registered direct offering are not satisfied and other risks set forth in the company’s filings with the Securities and Exchange Commission from time to time, including the risks set forth in the company’s annual report on Form 10-K for the year ended December 31, 2019 and other filings. These forward-looking statements speak only as of the date hereof, and Arcadia Biosciences, Inc. disclaims any obligation to update these forward-looking statements, except as required by law.

LinkedIn: Arcadia Biosciences
Twitter: @ArcadiaAg

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/arcadia-biosciences-rkda-announces-8-0-million-registered-direct-offering-priced-at-the-market-301196025.html

SOURCE Arcadia Biosciences, Inc.

Posted on

DS Smith drives real-time visibility adoption across North America with Transporeon and Sixfold

The partnership gives DS Smith the ability to manage all aspects of its regional transportation networks through one central control tower platform

FORT WASHINGTON, Pa., Dec. 18, 2020 (GLOBE NEWSWIRE) — DS Smith, a leading paper, packaging and recycling company with North American headquarters in Atlanta, moves ahead with its implementation of the next generation of supply chain technology by extending real-time visibility to its North American operations. In partnership with Transporeon, the leading global cloud platform for smart transportation management, and the Sixfold real-time visibility platform, DS Smith will continue to drive performance, data analysis, improved customer support and tackle the challenge of empty miles in vehicle movements across the United States.

Real-time visibility is another step in supporting the company’s vision of being the leading supplier of sustainable packaging solutions worldwide. The partnership will enable DS Smith to provide estimated time of arrival information and delivery updates to its customers, while also aiding in the identification of delay risks, detention management and key performance indicators that will be used to fuel ongoing performance analysis. As part of a global initiative to deliver integrated logistics as a standard, DS Smith capitalizes on the Transporeon connectivity platform as the backbone of a centralized control tower solution, integrating information from all relevant sources, including the company’s ERP system, rate data from the Transporeon sourcing platform, Sixfold shipment tracking and transport order management data from Transporeon Shipment Execution.

Aaron Clark, Interim Head of Procurement – NAPP at DS Smith, spoke about the anticipated benefits of the control tower solution in the “Logistics Process Excellence through Digitalization” educational session at CSCMP Edge 2020, saying that the ultimate goal will be the ability to respond quickly to market conditions and create additional opportunities for efficiencies in order to build a more resilient global transportation network.

“The data enables us to take everything to the next level that otherwise wouldn’t be possible—looking at our entire supply chain rather than just one site at a time,” says Clark. “We can now leverage Big Data from our Sixfold implementation to enable uniform, global visibility. Transporeon provides the data intelligence we need to be able to do that.”

Real-time visibility provided through Sixfold is just one offering in the Transporeon predictive transport assignment portfolio, created to enable truly digitized, smart and optimized supply chains across the world.

About DS Smith:

DS Smith is a leading provider of corrugated packaging, supported by recycling and papermaking operations. Headquartered in London and a member of the FTSE 100, DS Smith focuses on creating innovative sustainable packaging solutions in 34 countries employing around 30,000 people. Using the combined expertise of its divisions – Packaging, Recycling and Paper – DS Smith works with customers to deliver solutions that reduce complexity and deliver results throughout the supply chain. Its history can be traced back to the box-making businesses started in the 1940s by the Smith family.

About Transporeon

Transporeon boosts logistics performance and profitability with every freight load. Founded in Germany in 2000, Transporeon connects a worldwide network of more than 1,200 industrial shippers and retailers with over 100,000 logistics service providers in 100+ countries in real time. Its security-certified platforms offer digital solutions for freight benchmarking and sourcing, freight assignment and shipment execution, time slot management, shipment tracking, and end-to-end supply chain visibility. By leveraging the latest capabilities, including artificial intelligence and predictive analytics, Transporeon solutions cut CO2 emissions, empty runs and truck waiting times while digitizing manual processes. Transporeon is located across Europe, Russia, Asia and the US.

About Sixfold

Sixfold is Europe’s leading real-time transportation visibility platform, solving supply chain visibility challenges for the world’s biggest companies, shippers and carriers. Our mission is to provide transparency into areas of the b2b supply chain previously unseen and untracked, enabling businesses to cut costs and make more informed decisions. Sixfold’s platform, powered by AI, integrates with transport management systems, truck telematics and mapping data to proactively predict transportation delays, drive sustainability and deliver valuable business intelligence.

Krishna Gilligan
267-281-1634
[email protected]



Posted on

Diana Shipping Inc. Announces Sale of a Panamax Dry Bulk Vessel, the m/v Oceanis; and a Time Charter Contract for m/v New York

ATHENS, Greece, Dec. 18, 2020 (GLOBE NEWSWIRE) — Diana Shipping Inc. (NYSE: DSX), (the “Company”), a global shipping company specializing in the ownership of dry bulk vessels, today announced that it has signed, through a separate wholly-owned subsidiary, a Memorandum of Agreement to sell to an unaffiliated third party, the 2001-built vessel “Oceanis”, with delivery to the buyer latest by April 16, 2021, for a sale price of US$5.75 million before commissions.

The Company also announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with EGPN Bulk Carrier Co., Limited, Hong Kong, for one of its Capesize dry bulk vessels, the m/v New York. The gross charter rate is US$14,000 per day, minus a 5% commission paid to third parties, for a period until minimum April 16, 2022 up to maximum June 30, 2022. The charter is expected to commence on December 27, 2020.

The “New York” is a 177,773 dwt Capesize dry bulk vessel built in 2010.

This employment is anticipated to generate approximately US$6.57 million of gross revenue for the minimum scheduled period of the time charter.

Upon completion of the aforementioned sale and the previously announced sales of one Panamax dry bulk vessel, the m/v Coronis, and one Capesize dry bulk vessel, the m/v Sideris GS , Diana Shipping Inc.’s fleet will consist of 37 dry bulk vessels (4 Newcastlemax, 12 Capesize, 5 Post-Panamax, 5 Kamsarmax and 11 Panamax). As of today, the combined carrying capacity of the Company’s fleet, including the m/v Oceanis, the m/v Coronis and the m/v Sideris GS is approximately 5.0 million dwt with a weighted average age of 10.20 years. A table describing the current Diana Shipping Inc. fleet can be found on the Company’s website, www.dianashippinginc.com. Information contained on the Company’s website does not constitute a part of this press release.

About the Company

Diana Shipping Inc. is a global provider of shipping transportation services through its ownership of dry bulk vessels. The Company’s vessels are employed primarily on medium to long-term time charters and transport a range of dry bulk cargoes, including such commodities as iron ore, coal, grain and other materials along worldwide shipping routes.

Cautionary Statement Regarding Forward-Looking Statements

Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts.

The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words “believe,” “anticipate,” “intends,” “estimate,” “forecast,” “project,” “plan,” “potential,” “may,” “should,” “expect,” “pending” and similar expressions identify forward-looking statements.

The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, Company management’s examination of historical operating trends, data contained in the Company’s records and other data available from third parties. Although the Company believes that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies that are difficult or impossible to predict and are beyond the Company’s control, the Company cannot assure you that it will achieve or accomplish these expectations, beliefs or projections.

In addition to these important factors, other important factors that, in the Company’s view, could cause actual results to differ materially from those discussed in the forward-looking statements include the severity, magnitude and duration of the COVID-19 pandemic, including impacts of the pandemic and of businesses’ and governments’ responses to the pandemic on our operations, personnel, and on the demand for seaborne transportation of bulk products; the strength of world economies and currencies, general market conditions, including fluctuations in charter rates and vessel values, changes in demand for dry bulk shipping capacity, changes in the Company’s operating expenses, including bunker prices, drydocking and insurance costs, the market for the Company’s vessels, availability of financing and refinancing, changes in governmental rules and regulations or actions taken by regulatory authorities, potential liability from pending or future litigation, general domestic and international political conditions, potential disruption of shipping routes due to accidents or political events, vessel breakdowns and instances of off-hires and other factors. Please see the Company’s filings with the U.S. Securities and Exchange Commission for a more complete discussion of these and other risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.



Corporate Contact:
Ioannis Zafirakis
Director, Interim Chief Financial Officer, 
Chief Strategy Officer, Treasurer and Secretary
Telephone: + 30-210-9470-100
Email: [email protected]
Website: www.dianashippinginc.com

Investor and Media Relations:
Edward Nebb
Comm-Counsellors, LLC
Telephone: + 1-203-972-8350
Email: [email protected] 

Posted on

Unifor and Aleafia Health partner on groundbreaking medical cannabis coverage

TORONTO, Dec. 18, 2020 (GLOBE NEWSWIRE) — Unifor, Canada’s largest private-sector union and Aleafia Health Inc. (TSX: AH, OTC: ALEAF), have entered a long term partnership that through collective bargaining will seek to provide access for its members to medical cannabis coverage as part of their benefit and insurance coverage.

“This is a landmark agreement, with a union and a medical cannabis company coming together to provide dedicated support through medical marijuana clinics across the country while challenging the stigmas associated with cannabis,” said Jerry Dias, Unifor National President. “Partnering with Aleafia Health allows us to fight against Canada’s opiate crisis, and improve the lives of patients suffering from chronic pain.”

Unifor will work with its local unions to recommend and propose insurance coverage in collective bargaining agreements for the reimbursement of medical cannabis. In turn, Aleafia Health and its affiliates will provide Unifor members with access to its health and wellness ecosystem, including education and training, physician-led consultations, scripting, treatment and, where appropriate, medical cannabis products.

“This is a significant moment for the cannabis industry, and an important breakthrough for medical cannabis accessibility in Canada. Every day, our team of medical professionals see the benefits of cannabis in the lives of our patients,” said Aleafia Health CEO Geoffrey Benic. “Due to the progressive leadership of Unifor, and Aleafia Health’s well-earned reputation for providing excellence in cannabinoid therapy, we will be able to expand these benefits to union members across Canada.”

Increased access to medical cannabis coverage may also provide further cost savings and health benefits to both members and employers, including a reduction in reliance on traditional pharmaceutical prescriptions.

The two parties have signed a binding letter of intent which outlines the terms of one or more definitive agreements. Details of the proposed transaction are to be settled following comprehensive due diligence between Aleafia Health and Unifor, and the closing of the transaction is subject to customary closing conditions, including approval by each party’s respective board of directors.

For media inquiries or to arrange interviews via FaceTime, Zoom or Skype with Dias or Benic please contact:

Hamid Osman, Unifor Communications Representative
647-448-2823 (cell) [email protected]

Nicholas Bergamini, VP Investor Relations
1-833-879-2533 [email protected]

About Unifor:

https://www.unifor.org/en/about-unifor

Unifor is Canada’s largest union in the private sector, representing 315,000 workers in every major area of the economy. The union advocates for all working people and their rights, fights for equality and social justice in Canada and abroad, and strives to create progressive change for a better future.

About Aleafia Health:
www.AleafiaHealth.com

Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada and in international markets. The Company operates medical clinics, education centres and production facilities for the production and sale of cannabis.

Aleafia Health owns three significant licensed cannabis production facilities, including the first large-scale, legal outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of commercially proven, high-margin derivative products including oils, capsules and sprays. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and operates internationally in three continents.

Innovation, the heart of Aleafia Health’s competitive advantage, has led to the Company maintaining a medical cannabis dataset with over 10 million data points to inform proprietary illness-specific product development and its highly differentiated education platform FoliEdge Academy. The Company is committed to creating sustainable shareholder value; the TSX Venture Exchange named Aleafia the 2019 top performing company prior to its graduation to the TSX.

Forward Looking Information

This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.



Posted on

Carl S. Ewusiak named as President and elected to the Board of Directors of Empire Diversified Energy, Inc.

PR Newswire

FORT LAUDERDALE, Fla., Dec. 18, 2020 /PRNewswire/ — Empire Diversified Energy, Inc. (OTCQB: MPIR), announced today that Carl (Scotty) Ewusiak has been unanimously named to the Board of Directors of the Company, as well as approved by the Board to serve as Empire’s President.  Empire recently closed on a $26 million tax-exempt funding with the West Virginia Economic Development Authority, underwritten by Citigroup, and subscribed by Principal Street Partners, and Nuveen.  Mr. Ewusiak has for many years functioned as owner and operator of the facilities in and around Follansbee, West Virginia that were acquired by Empire as a first phase in a broader project of acquisition and development in the area.  According to Lawrence Chimerine, Chairman of the Board of Directors of Empire Diversified Energy Corp.: “Scotty’s extensive experience in the area, his contacts and associations developed over the years, and the broad success that he has achieved create a dynamic combination for Empire’s management team.”

A more detailed recitation of Mr. Ewusiak’s bio, as well as a more comprehensive presentation of the Empire Diversified Energy Corp.’s funding and acquisitions is to be found at the website: www.empirediversified.com.

About Empire Diversified Energy, Inc.

Empire Diversified Energy, Inc. is a full-service company offering logistic and service solutions to the dynamic changing needs of the energy industry. The Company’s goal, based on years of demonstrable experience, is to develop a network of logistics and storage facilities to promote international sales of petrochemicals and other materials.

Statements contained in this communication that are not based upon current or historical fact are forward-looking in nature. Such forward-looking statements, including our expectations regarding the closing and timing of the bond issuances and receipt of any proceeds therefrom and are subject to certain risks, uncertainties, and assumptions. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected, or described pursuant to similar expressions.

Cision View original content:http://www.prnewswire.com/news-releases/carl-s-ewusiak-named-as-president-and-elected-to-the-board-of-directors-of-empire-diversified-energy-inc-301196019.html

SOURCE Empire Diversified Energy Inc.